-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 17, Haisco issued an announcement that its wholly-owned subsidiary Liaoning Haisco Pharmaceutical Co.
The long-chain fat emulsion/amino acid (16)/glucose (16%) injection developed by the generic drug product obtained the drug registration approval issued by the National Medical Products Administration in July 2018 (batch number: 2018S00429).
Medium and long-chain fat emulsion/amino acid (16)/glucose (16%) injection is a "all-in-one" parenteral nutrition injection, used when oral or enteral nutrition cannot be carried out, insufficient or contraindicated, this product is light Patients with moderate to severe catabolism provide the energy, essential fatty acids, amino acids, electrolytes and fluids needed for parenteral nutrition therapy.
Upon inquiry, the original product of the medium and long-chain fat emulsion/amino acid (16)/glucose (16%) injection is the "all-in-one" parenteral nutrition preparation developed by the German company B, Braun Melsungen AG, and the trade name is "NuTRIflex® Lipid" peri" was first approved for listing in Sweden in 1999.
According to data from Meinenet, the sales of medium and long-chain fat emulsion/amino acid (16)/glucose (16%) injection in urban public and county-level public hospitals in 2020 will be about 45 million yuan.
